Tag: aduro biotech

February 11, 2019

Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100

Aduro Biotech (NASAQ:ADRO) has announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 for...
December 19, 2018

Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies

Eli Lilly (NYSE:LLY) and Aduro Biotech (NASDAQ:ADRO) today announced a research collaboration and exclusive license agreement for Aduro’s cGAS-STING Pathway...
December 17, 2018

Biotech Trends 2018: Immuno-oncology Disappoints

2018 marked another critical year of growth for the biotech market. Learn about key biotech trends before the new year...
June 8, 2018

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership

Aduro Biotech (NASDAQ:ADRO) announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with nivolumab for...